Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With COVID-19 Pneumonia

X
Trial Profile

Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With COVID-19 Pneumonia

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 17 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reparixin (Primary) ; Reparixin (Primary)
  • Indications COVID 2019 infections; COVID-19 pneumonia; Respiratory insufficiency
  • Focus Therapeutic Use
  • Acronyms REPAVID-19
  • Sponsors Dompe Farmaceutici
  • Most Recent Events

    • 13 Jun 2022 According to a Dompe Farmaceutici media release, results from this trial were presented at the scientific sessions of the American Thoracic Society 2022 International Conference.
    • 13 Jun 2022 Results published in the Dompe Farmaceutici Media Release.
    • 26 May 2022 Primary endpoint has been met. (Phase 2 - Percentage of Participants With Composite Endpoint of Clinical Events), as per Results published in the Infectious Diseases and Therapy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top